Geode Capital Management
MCRB icon

Geode Capital Management’s Seres Therapeutics MCRB Stock Holding History

Geode Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$664K Sell
74,835
-11,307
-13% -$132K ﹤0.01% 3481
2025
Q4 		$1.28M Buy
86,142
+1,160
+1% +$20.2K ﹤0.01% 3306
2025
Q3 		$1.64M Sell
84,982
-6,620
-7% -$106K ﹤0.01% 3250
2025
Q2 		$1.02M Buy
91,602
+10,663
+13% +$93.8K ﹤0.01% 3319
2025
Q1 		$1.13M Buy
80,939
+5,417
+7% +$84.8K ﹤0.01% 3263
2024
Q4 		$1.26M Buy
75,522
+6,090
+9% +$99K ﹤0.01% 3284
2024
Q3 		$1.31M Buy
69,432
+12,751
+22% +$259K ﹤0.01% 3254
2024
Q2 		$821K Sell
56,681
-49,951
-47% -$833K ﹤0.01% 3385
2024
Q1 		$1.65M Buy
106,632
+1,930
+2% +$41.6K ﹤0.01% 3188
2023
Q4 		$2.93M Buy
104,702
+5,324
+5% +$140K ﹤0.01% 2965
2023
Q3 		$4.73M Buy
99,378
+1,310
+1% +$100K ﹤0.01% 2666
2023
Q2 		$9.39M Buy
98,068
+16,293
+20% +$1.77M ﹤0.01% 2320
2023
Q1 		$9.27M Buy
81,775
+2,255
+3% +$244K ﹤0.01% 2297
2022
Q4 		$8.91M Buy
79,520
+4,195
+6% +$562K ﹤0.01% 2339
2022
Q3 		$9.67M Buy
75,325
+14,388
+24% +$1.47M ﹤0.01% 2287
2022
Q2 		$4.18M Buy
60,937
+471
+0.8% +$40.6K ﹤0.01% 2801
2022
Q1 		$8.61M Sell
60,466
-1,402
-2% -$216K ﹤0.01% 2454
2021
Q4 		$10.3M Buy
61,868
+14,101
+30% +$2.24M ﹤0.01% 2424
2021
Q3 		$6.65M Sell
47,767
-7,549
-14% -$1.48M ﹤0.01% 2743
2021
Q2 		$26.4M Buy
55,316
+6,664
+14% +$2.81M ﹤0.01% 1784
2021
Q1 		$20M Buy
48,652
+4,350
+10% +$2M ﹤0.01% 1880
2020
Q4 		$21.7M Buy
44,302
+4,345
+11% +$2.54M ﹤0.01% 1671
2020
Q3 		$22.6M Buy
39,957
+3,051
+8% +$1.01M ﹤0.01% 1453
2020
Q2 		$3.51M Buy
36,906
+3,820
+12% +$335K ﹤0.01% 2524
2020
Q1 		$2.36M Buy
33,086
+2,039
+7% +$137K ﹤0.01% 2584
2019
Q4 		$2.14M Buy
31,047
+3,654
+13% +$271K ﹤0.01% 2960
2019
Q3 		$2.2M Buy
27,393
+4,338
+19% +$287K ﹤0.01% 2893
2019
Q2 		$1.48M Buy
23,055
+9,157
+66% +$869K ﹤0.01% 3098
2019
Q1 		$1.91M Buy
13,898
+2,009
+17% +$245K ﹤0.01% 2883
2018
Q4 		$1.07M Buy
11,889
+574
+5% +$80.3K ﹤0.01% 3086
2018
Q3 		$1.72M Sell
11,315
-5
-0% -$809 ﹤0.01% 2975
2018
Q2 		$1.95M Sell
11,320
-56
-0.5% -$9.15K ﹤0.01% 2877
2018
Q1 		$1.67M Buy
11,376
+906
+9% +$174K ﹤0.01% 2864
2017
Q4 		$2.12M Buy
10,470
+1,906
+22% +$392K ﹤0.01% 2717
2017
Q3 		$2.75M Buy
8,564
+59
+0.7% +$16.1K ﹤0.01% 2566
2017
Q2 		$1.92M Buy
8,505
+189
+2% +$38.8K ﹤0.01% 2753
2017
Q1 		$1.87M Buy
8,316
+453
+6% +$91.9K ﹤0.01% 2705
2016
Q4 		$1.56M Buy
7,863
+866
+12% +$189K ﹤0.01% 2774
2016
Q3 		$1.72M Buy
6,997
+2,501
+56% +$878K ﹤0.01% 2648
2016
Q2 		$2.61M Buy
4,496
+647
+17% +$380K ﹤0.01% 2308
2016
Q1 		$2.04K Buy
3,849
+94
+3% +$49.1K ﹤0.01% 2448
2015
Q4 		$2.63M Buy
3,755
+426
+13% +$280K ﹤0.01% 2298
2015
Q3 		$1.97M Buy
+3,329
New +$2.72M ﹤0.01% 2450

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management's MCRB Position: Q1 2026 in Review

Geode Capital Management reduced its Seres Therapeutics (MCRB) stake by 13% in Q1 2026, selling an estimated $132K and leaving 74,835 shares worth $664K. The position accounts for ﹤0.01% of the portfolio, ranked #3481.

Geode Capital Management first reported a position in MCRB in Q3 2015 and has held it in 43 quarters since. The position peaked at $26.4M in Q2 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Geode Capital Management held 74,835 shares of Seres Therapeutics worth $664K as of Q1 2026.
  • Geode Capital Management sold 11,307 Seres Therapeutics shares in Q1 2026, an estimated $132K.
  • Seres Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3481 holding.
  • Geode Capital Management first reported a position in Seres Therapeutics in Q3 2015 and has held it in 43 quarters since.
  • Geode Capital Management's Seres Therapeutics position peaked at $26.4M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.